What is the difference between terbutaline and nitroglycerin in terms of clinical use and pharmacokinetics?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 30, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Terbutaline vs Nitroglycerin: Pharmacokinetics and Clinical Use

Fundamental Pharmacologic Distinction

Terbutaline is a beta-2 adrenergic agonist used for bronchodilation and uterine relaxation, while nitroglycerin is a nitrate vasodilator used for cardiac ischemia, heart failure, and hypertensive emergencies—these are entirely different drug classes with distinct mechanisms, pharmacokinetics, and clinical applications. 1


Mechanism of Action

Nitroglycerin

  • Acts as an endothelium-independent vasodilator that dilates both venous capacitance vessels (predominantly) and arterial vessels, reducing myocardial oxygen demand and enhancing oxygen delivery 1
  • Dilates epicardial coronary arteries and promotes collateral flow to ischemic regions 1
  • Venodilation decreases preload, which reduces left ventricular filling pressure—critical for acute pulmonary edema 2

Terbutaline

  • Stimulates beta-2 adrenergic receptors, causing smooth muscle relaxation in bronchi and uterine tissue 1
  • Provides more effective tocolysis with less impact on maternal blood pressure compared to nitroglycerin 3

Pharmacokinetic Profiles

Nitroglycerin

  • Onset of action: 1-5 minutes intravenously 4
  • Duration of action: 3-5 minutes intravenously 4
  • Dosing: Initial IV dose 5-10 mcg/min, titrate by 5-10 mcg/min every 3-5 minutes, maximum 200 mcg/min 4, 2
  • Critical limitation: Rapid tolerance develops within 24-48 hours with continuous use, requiring dose escalation 5
  • Absorption issues: Significant interaction with PVC tubing—initial dosing should be 10-20 mcg/min if using standard PVC tubing 5

Terbutaline

  • Onset of action: Rapid (minutes) when given subcutaneously 6
  • Duration of action: Substantially longer than epinephrine—8 to 12 times longer duration than nitroglycerin for similar effects 7
  • Dosing: 0.25 mg subcutaneously for tocolysis; 250 mcg IV for acute intrapartum fetal resuscitation 3, 8

Clinical Applications: When to Use Each

Nitroglycerin Indications

  • Acute coronary syndrome with hypertension: IV nitroglycerin for ongoing ischemic symptoms not relieved by sublingual doses 1
  • Acute cardiogenic pulmonary edema: High-dose IV nitroglycerin (combined with low-dose furosemide) reduces intubation rates and myocardial infarction 4, 1
  • Hypertensive emergency with cardiac involvement: Only when accompanied by acute pulmonary edema or acute coronary syndrome—NOT for isolated severe hypertension 5
  • Alternative for uterine relaxation: Can be used for placental removal, though terbutaline is more effective 1

Terbutaline Indications

  • Acute bronchospasm: At least as effective as epinephrine for reversible bronchospasm in stable asthmatics 6
  • External cephalic version: Significantly higher success rate (55% vs 23%) compared to nitroglycerin 8
  • Acute intrapartum fetal resuscitation: Provides more effective tocolysis with lower median contraction frequency (2.9 vs 4 per 10 minutes) and reduced tachysystole (1.8% vs 18.9%) compared to nitroglycerin 3

Hemodynamic Effects: Critical Differences

Nitroglycerin

  • Blood pressure: Causes significant decrease in mean arterial pressure (81 to 76 mm Hg) 3
  • Contraindicated if systolic BP <90 mmHg: Vasodilators compromise organ perfusion below this threshold 5
  • Target BP reduction: Only 20-25% reduction in mean arterial pressure in first hour to avoid organ hypoperfusion 5, 2
  • Monitoring requirement: Continuous BP monitoring with arterial line recommended for borderline pressures 5

Terbutaline

  • Blood pressure: Minimal impact on maternal blood pressure (82 to 81 mm Hg, not significant) 3
  • Heart rate: Increases maternal heart rate and causes palpitations (17.2% incidence vs 0% with nitroglycerin) 8
  • Cardiovascular safety: No cardiovascular side effects of significance noted in stable asthmatics 6

Critical Safety Considerations

Nitroglycerin Contraindications

  • Absolute contraindications: Systolic BP <90 mmHg, phosphodiesterase inhibitor use within 24 hours (sildenafil) or 48 hours (tadalafil), right ventricular infarction, severe aortic stenosis, volume depletion 1, 2
  • Adverse effects: Headache (frequent), hypotension (particularly with abrupt administration), reflex tachycardia 4, 5
  • Drug interaction: Avoid with sodium nitroprusside in acute MI—nitroprusside decreases regional blood flow and increases myocardial damage 4

Terbutaline Contraindications

  • Relative contraindications: History of 2nd or 3rd degree AV block, systolic heart failure, asthma (for beta-blockers, not terbutaline), bradycardia 4
  • Adverse effects: Palpitations, increased heart rate, tremor 8

Comparative Efficacy in Obstetric Use

For external cephalic version, terbutaline is superior to nitroglycerin with a success rate of 55% vs 23% (P = 0.01). 8

  • For acute intrapartum fetal resuscitation, both agents have similar success rates (terbutaline 71.9% vs nitroglycerin 64.2%, P = 0.38), but terbutaline provides more effective uterine relaxation 3
  • Terbutaline reduces contraction frequency more effectively (2.9 vs 4 per 10 minutes, P < 0.002) and reduces tachysystole (1.8% vs 18.9%, P = 0.003) 3

When NOT to Use Nitroglycerin

  • Isolated hypertensive emergency without cardiac involvement: Use nicardipine or labetalol instead 5
  • Hypertensive urgency: Use oral agents (captopril, labetalol, or extended-release nifedipine) 5
  • Eclampsia/preeclampsia: Use hydralazine, labetalol, or nicardipine 5
  • Acute renal failure: Use clevidipine, fenoldopam, or nicardipine 5

References

Guideline

Pharmacology and Clinical Use of Terbutaline and Nitroglycerin

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Nitroglycerin in Acute Pulmonary Edema

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Nitroglycerin Drip in Hypertensive Emergency

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.